This study describes a new strategy for the identification of squamous carcinoma antigens tumor-associated antigens (TAA). The antigens were discovered by comparing microarrays of squamous carcinoma vaccines highly enriched for immunotherapeutic cells with non-enriched vaccines. The vaccines were prepared by transferring sheared genomic DNA fragments (25 kb) from KLN205 cells, a squamous carcinoma cell line (DBA/2 mouse origin (H-2 d ) into LM fibroblasts (C3H/He origin, H-2 k ). The transferred tumor DNA segments integrate spontaneously into the genome of the recipient cells, replicate as the cells divide and are expressed. As only a small proportion of the transfected cell population was expected to have incorporated DNA segments that included genes specifying TAA (the vast majority specify normal cellular constituents), a novel strategy was employed to enrich the vaccine for TAA-positive cells. Microarrays were used to compare genes expressed by enriched and non-enriched vaccines. Seventy-five genes were overexpressed in cells from the enriched vaccine. One, the gene for Cytochrome P450 (family 2, subfamily e, polypeptide 1) (Cyp2e1), was overexpressed in the enriched but not the non-enriched vaccine. A vaccine for squamous carcinoma was prepared by transfer of a 357 bp fragment of the gene for Cyp2e1 into the fibroblast cell line. Robust immunity, sufficient to result in indefinite survival, was induced in tumor-bearing mice immunized with cells transfected with this gene fragment.
Introduction
The annual worldwide incidence of squamous carcinoma of the head and neck (SCCHN) is approximately 500 000. It is the fifth leading cause of cancer-related death. The frequency of death of patients with metastatic SCCHN has remained essentially constant for the last 30 years, in spite of more sensitive methods of detection, improved surgical/radiotherapeutic techniques and novel chemotherapeutic agents. 1 The 5-year survival is poor. New treatment options are urgently needed.
The potential benefits of immunotherapy as an adjunct to conventional forms of treatment of various types of cancer including metastatic SCCHN are well established. [2] [3] [4] [5] [6] Activated cytotoxic T lymphocytes (CTL), which are capable of recognizing and destroying cancer cells, are generated in mice, and patients receiving various forms of immune-based therapies. In most instances, the immunity is directed toward unique major histocompatibility complex (MHC) class I-restricted tumor-associated antigens (TAA) expressed by the malignant cells.
TAA have been identified in various human malignancies by comparing the microarrays of primary cancers or cancer cell lines with the homologous non-malignant tissue. 7, 8 Although multiple TAA have been identified by this method, there is no assurance that they are 'therapeutic,' in the sense that immunity to the identified antigen will result in rejection of the neoplasm. Immunization of melanoma patients with a gp100-derived peptide, stimulated strong CTL responses in patients, for example, without clinical responses. 9 In an analogous study, immunization with melanoma antigen recognized by autologous T-cells (MART)-1, a known melanomaassociated antigen, generated an increase in MART-1-specific CTL. Tumor regression was not observed. 10 Another concern is that cellular cancer vaccines including vaccines prepared by transfer into dendritic cells (DC) of tumor-derived extracts such as messenger RNA, 11, 12 tumor cell lysates, 13, 14 apoptotic cell bodies, 15, 16 among others, 17 may not contain a sufficient number of cells that express TAA. It is highly likely that the vast majority of cells in such vaccines express normal cellular constituents, which are unrelated to the induction of immunity to the neoplasm. Immunization with a vaccine enriched for cells that express TAA is likely to induce enhanced antitumor immunity, improving its therapeutic benefits.
Few tumor antigens, including antigens associated with SCCHN, have been identified. TAA-specific T-cell clones from cancer patients have been used to identify tumor antigens. 18 Genetic mutations resulting in the aberrant or overexpression of molecules commonly expressed by nonmalignant cells appear to underlie their immunogenic properties. 19, 20 MAGE-A4 and NY-ESO-1 cancer testis antigens were identified in the malignant cells of patients with non-small cell lung cancer. 21 Cancer testis antigens were also associated with the malignant cells of patients with SCCHN. 22 CTL from a patient with esophageal carcinoma recognized an human leukocyte antigen-A2601-restricted peptide encoded by the SART-1 gene. 23 The presence of tumor infiltrating CD4 þ T cells correlated with an improved outcome in patients with SCCHN. 24 It is likely that these identified TAA were only a few representations of an array of tumor antigens, which were present among the malignant cell population. Genetic instability is a notorious characteristic of cancer cells. [25] [26] [27] [28] In prior reports, 29 we described the results of studies designed to enrich a cellular vaccine for squamous cell carcinoma (SCC) for cells that expressed TAA. The vaccine was prepared by transfer of DNA-fragments from KLN205 cells, an aggressive squamous carcinoma cell line of DBA/2 mouse origin (H-2 d ), into LM cells, a mouse fibroblast cell line that expressed allogeneic MHC class I determinants (H-2 k ). As the transferred DNA integrates spontaneously into the genome of the recipient cells, replicates as the cells divide, and is expressed, sufficient DNA to prepare the vaccine could be obtained from small primary neoplasms. DNA isolated from as few as 10 million cells (4 mm tumor) was sufficient. 30 In this report, we describe a new strategy for the identification of antigens associated with SCC that induce therapeutic immune responses in tumor-bearing mice. Microarrays of vaccines enriched for immunotherapeutic cells were compared with microarrays of non-enriched vaccines. Our objective was to identify genes uniquely expressed by the enriched vaccines. One, the gene specifying Cyp2e1, a variant of cytochrome P450, was present in arrays of enriched but not non-enriched vaccines. Tumor-bearing mice with established SCC treated solely by immunization with an allogeneic fibroblast cell line modified to express a 357 bp fragment of the Cyp2e1 gene survived significantly longer than mice in various control groups, identifying this epitope as a therapeutic determinant expressed by the SCC.
Materials and methods
Experimental animals, tumor cell lines and mAbs Eight-to 10-week-old pathogen-free DBA/2 female mice (H-2 d ) were from the Jackson Laboratory (Bar Harbor, ME). The animals, between 10 and 14 weeks old when used in the experiments, were maintained according to NIH Guidelines for the Care and Use of Laboratory Animals. KLN205 cells, a highly aggressive squamous carcinoma cell line derived from the Nettelsheim lung carcinoma, 31 were from the American Type Culture Collection (ATCC). LM cells, a fibroblast cell line of C3H/He mouse origin, B16F1 cells, a melanoma cell line of C57BL/6 mouse origin and LM fibroblasts were from the ATCC. Each of the cell types was maintained at 371 in a humidified 7% CO 2 /air atmosphere in Dulbecco's modified Eagle's medium (Gibco BRL, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum and antibiotics (Gibco BRL) (growth medium). Monoclonal antibodies (mAbs) for CD4 þ , CD8 þ and NK1.1 cells were from B-D Pharmingen (San Jose, CA).
Isolation of genomic DNA from KLN205 cells A DNeasy isolation kit (Qiagen, Valencia, CA) was used to obtain genomic DNA from the tumor cells, as described previously. 29 The extracted DNA was loaded onto a DNeasy spin column and eluted after two washes with buffer. The A 260 /A 280 ratio of the isolated DNA was greater than 1.8 in each instance. The molecular size of the extracted DNA was approximately 25 kb, as determined by agarose gel electrophoresis.
Modification of LM fibroblasts to secrete IL-2
As a means of augmenting their nonspecific immunogenic properties, the fibroblasts were modified to secrete interleukin (IL)-2 before transfection with DNA from the SCC (LM-IL-2 cells), as described previously. 29 A vector (pZipNeoSV-IL-2; from MKL Collins, University College, London, England) specifying human IL-2 was used for this purpose. (Human IL-2, like mouse IL-2, stimulates the growth and maturation of mouse T cells.)
Modification of the cytokine-secreting fibroblasts to express H-2K b -class I-determinants, allogeneic in DBA/2 mice Allogeneic class I-determinants are strong immune adjuvants. 32, 33 To stimulate uptake of the vaccine by DCs of the tumor-bearing mice, and to ensure rejection, the fibroblasts (H-2 k ) were modified to express additional
b -determinants was used, as described previously. 29, 32 Immunofluorescent staining and cytofluorometric measurements Quantitative immunofluorescence measurements were employed to measure the expression of MHC class Ideterminants by the fibroblasts used as recipients of DNA from the SCC, as described previously. 29 The measurements were performed in DAKO CyAn cytofluorograph (Fort Collins, CO) using Summit V4.2 software. Oneparameter fluorescence histograms were generated by analyzing at least 1 Â 10 5 cells.
Preparation of the DNA-based cellular vaccine
The vaccine was prepared by transfer of sheared unfractionated DNA fragments from KLN205 cells into the modified fibroblasts. For use as a control, the same procedure was used to transfer DNA from B16F1 cells into the fibroblasts. The method described by Wigler et al. 34 was applied, as modified.
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Mouse IFN-g ELISPOT assays Mouse enzyme-linked immunosorbent spot assay (ELI-SPOT) interferon gamma (IFN-g) assays were used to detect the presence of T cells responsive to KLN205 cells in mice immunized with the transfected fibroblasts, as described previously. 29 The spots were counted by computer-assisted image analysis (ImmunoSpot Series 2 analyzer: Cellular Technology Limited, Cleveland, OH).
Detection of CTLs reactive with KLN205 cells by 51
Cr-release cytotoxicity assays A standard 51 Cr-release cytotoxicity assay was used to detect the presence of spleen cells with cytotoxic activity toward KLN205 cells in mice immunized with the transfected fibroblasts. Spleen cell suspensions were coincubated under standard cell culture conditions for 5 days with (mitomycin C treated) KLN205 cells, as described previously. 29 The ratio of spleen cells to mitomycin-C-treated SCC during the co-incubation was 30:1. At the end of the 5-day co-incubation period, the population that failed to adhere to the plastic cell culture flasks was collected and used as the source of effector cells for the cytotoxicity determinations.
The percent specific cytolysis was calculated as: The spontaneous release of 51 Cr was less than 15% of the total release in each instance.
Microarrays of vaccines enriched for transfected fibroblasts that induced immunity to the SCC Microarrays were used to determine the gene expression profiles of transfected fibroblasts enriched for cells that induced immunity to the SCC. The concentration and purity of total RNA derived from each cell suspension was measured at OD260/280 and the quality of the RNA sample was assessed using an Agilent Bioanalyzer with the RNA6000 Nano Lab Chip (Agilent Technologies, Santa Clara, CA, USA). Biotin-labeled complementary RNA (cRNA) was prepared by linear amplification of the Poly (A) þ RNA population within the total RNA sample. Purified cRNA (10 mg) was fragmented to uniform size and applied to CodeLink Mouse 20K Bioarrays (GE Healthcare, Fairfield, CT, USA) in hybridization buffer. CodeLink Mouse Whole-Genome arrays are comprised of approximately 36 000 30-mer probes. CodeLink Expression Analysis software (GE Healthcare) was used to process the scanned images. Only genes that had values greater than background intensity in at least one treatment condition were used for further analysis. Using a ratio interpretation of the data and normalization of each gene to the median intensity across conditions, the data were filtered by expression intensity for genes that did not vary by 50% across all samples within the experiment. Genes in treated groups that had ratios greater than 2.0 and less than 0.5 (twofold changes) relative to controls were considered as candidates for further analysis.
RT-PCR of candidate genes identified by microarrays of the enriched vaccines
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine if the selected genes were expressed. RNA was isolated using RNeasy Kits from Qiagen (Valencia, CA), according to the manufacturer's instructions. In brief, cells grown in monolayer (about 6 Â 10 6 ) were disrupted by addition of 600 ml of RNA lysis buffer for tissue (RLT) with 1 v/v% b-mercaptoethanol. The cells were homogenized and one volume of 70% ethanol was added before the extracts were loaded onto RNeasy mini columns. RT-PCR was performed with a one-step RT-PCR kit from Qiagen (Valencia, CA), according to the manufacturer's instructions. The reverse transcriptase reaction was performed at 501C for 45 min. The PCR reaction was at 941C denaturation step for 2 min, 581 annealing step for 1 min and 721C extension for 2 min for 35 cycles using a DNA Thermal Cycler 480 (Perkin-Elmer, Wellesley, MA). The primers used for the analysis of the Cyp2e1 gene were as follows:
Preparation of an expression vector (pcDNA6/V5-HisA/ Cyp2e1) that included the gene for Cyp2e1
The RT-PCR product of Cyp2e1 was ligated into a pCR 2.1. vector using a TA 2.1 cloning kit from Invitrogen (Carlsbad, CA), according to the manufacturer's instructions. In brief, 50 ng pCR2.1 and 2 ml of the PCR product containing 10 ng Cyp2e1 was mixed with buffer and 1 ml T4 DNA ligase in 10 ml total volume and incubated at 141C for 4 h. Ligation mixture (5 l) containing pCR2.1/ Cyp2e1 was transferred into 50 ml DH5a competent cells followed by a 30 min incubation on ice. Afterward, the cells were subjected to a 20 s heat shock at 371C and 2 min additional incubation on ice. As a control, pUC 19 DNA 5 ml was also transferred into DH5a competent cells. The transformation complex was mixed with 950 ml super optimal broth for catobolite repression (SOC) medium and incubated at 371C for 1 h. The cell pellets were plated on Luria-Bertani (LB) agar plates containing 100 mg/ml ampicillin and 1 mg X-Gal and incubated at overnight at 371C. White colonies indicating the insertion of Cyp2e1 gene in the lacZ site of pCR2.1 were selected and amplified. DNA from each amplified clone was extracted and digested with EcoRI enzyme to verify the 357 bp Cyp2e1 gene fragment. The resulting band was recovered from the gel and purified from a Gel-purification kit (Qiagen, Valencia, CA). The 357 bp portion of the Cyp2e1 gene was ligated into the expression vector pcDNA6/V5-HisA (Invitrogen, Carlsbad, CA). As a control, pUC 19 DNA 5 ml was also transferred into DH5a competent cells. The transformation complex was mixed with 950 ml SOC medium and incubated at 371C for 1 h. The cell pellets were plated on LB agar plates containing 100 mg/ ml ampicillin and incubated at 371C overnight. Colonies were selected and amplified in 2 ml cultures for DNA isolation and Cyp2e1 verification through EcoRI digestion. The identified pcDNA6/V5-HisA/ Cyp2e1 clone was amplified in 2 l cultures and 1.26 mg of pcDNA6/V5-HisA/ Cyp2e1 DNA was obtained using a plasmid maxi prep kit (Qiagen, Valencia, CA).
Transfection of the modified fibroblasts with the Cyp2e1-vector (LM-IL-2K b / Cyp2e1) to prepare a vaccine for treatment of mice with SCC A vaccine for SCC was prepared by transfection of LM fibroblasts with the Cyp2e1-vector. The fibroblasts were modified beforehand to secrete IL-2 and to express
6 ) were plated in four 100 mm plates in mouse growth medium (MGM) without antibiotics. Afterward, 30 mg of pcDNA6/V5-HisA/ Cyp2e1 DNA, which includes a gene conferring resistance to blasticidin, in 2 ml Opti medium was mixed with 100 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA) followed by incubation for 20 min at room temperature. A total of 1 ml of the 4 ml transfection complex (pcDNA6/V5-HisA/ Cyp2E1 DNA and Lipofectamine 2000) was added to each of the four plates and incubated overnight in at 371C in a 7% CO 2 /air incubator. The number of cells in the four plates was expanded to 16 plates and selected in growth medium containing 5 mg/ml blasticidin. Non-transfected cells in control plates (without pcDNA6/V5-HisA, i.e., without the blasticidin-resistance gene) died within 5 days. The transfected viable cells were allowed to proliferate for 7 additional days and pooled. One half of the cell suspension was maintained frozen/viable; the remaining portion was maintained at 371C in a 7% CO 2 /air incubator in selection medium. As a control, the same procedure was followed except that the LM-IL-2K b cells were transfected with the 'empty' vector pCDNA6/V5-HisA. The transfection and expression of the Cyp2e1 gene was confirmed by RT-PCR of the resulting vaccine (LM-IL-2K b /Cyp2e1).
Statistical analyses
Kaplan-Meier log-rank analyses were used to determine the statistical differences between the survival of mice in the various experimental and control groups. A P-value less than 0.05 was considered significant. Student's t-test one-way ANOVA was used to determine the statistical differences between experimental and control groups in the experiments performed in vitro.
Results

IL-2-secretion and expression of H-2K
b -determinants by modified LM fibroblasts, used as recipients of DNA from the squamous carcinoma cells Among other advantages, the use of a fibroblast cell line as the recipient of DNA from the SCC enabled the cells to be conveniently modified in advance of DNA transfer to augment their nonspecific immunogenic properties. In this instance, the cells, of C3H/He mouse origin, were modified to secrete IL-2 by transduction with the plasmid pSV2NeoIL-2, as described previously. 29 The fibroblasts were also modified to express H-2K b -determinants (LM-IL-2K b cells) to stimulate uptake by DCs of tumor-bearing DBA/2 mice. A plasmid, pBR327H-2K b , specifying H-2K b -determinants was used for this purpose, as described previously. 29 The expression of H-2K bdeterminants by the transduced cells was a stable property. The staining intensity was essentially unchanged after 3 months of continuous culture.
Enrichment of the vaccine for cells that induced immunity to (KLN205) squamous carcinoma cells
The vaccine was prepared by transfer of genomic DNA fragments from KLN205 cells into the modified fibroblasts. As only a small proportion of the transfected cell population was expected to have incorporated DNA segments that specified TAA, the vaccine was enriched for immunotherapeutic cells, as described previously. 29 In brief, 10 pools of transfected cells were established. Each pool contained a starting inoculum of 1 Â 10 3 cells. We reasoned that if the starting inoculums were sufficiently small, then the number of TAA-positive and TAA-negative cells in each of the individual pools would not be expected to be the same. Wells containing higher numbers of TAA-positive cells could be detected by the response of DBA/2 mice to immunization with cells from the individual pools, as determined by both ELISPOT IFN-g and 51 Cr-release cytotoxicity assays. To obtain a sufficient number of cells for immunization, the number of cells in each pool was allowed to increase to approximately 5 Â 10
7
. A portion of each of the expanded cell populations was maintained frozen/viable (for later recovery). The remaining portion was used for immunization. Frozen cells derived from the pool that stimulated immunity to KLN205 cells to the greatest extent (immuno high ), and, for use as a control, from the pool that induced immunity to KLN205 cells to the least extent (immuno low ), were recovered, reestablished in culture and subjected to additional rounds of positive or negative selection. The enrichment strategy resulted in a progressive increase in the immunogenic properties of the cells from the immuno high pools, as described previously.
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Microarrays of cells from the immuno high and immuno low pools Cells from the immuno high and the immuno low pools were analyzed by microarray. Seventy-five genes were upregulated and 25 genes were downregulated in cells from the immuno high pool, in comparison to cells from the immuno low pool (Table 1) . Eight genes that were up-or downregulated to the greatest extent in cells from the immuno high pool were selected for analysis by RT-PCR (Table 2) . One, the gene for cytochrome P450 (Cyp2e1), was expressed in cells from the immuno high pool and in KLN205 cells, but not in cells from the immuno low pool (Figure 1a) . Each of the other genes analyzed was expressed to an equivalent extent in cells from the immuno high and the immuno low pools.
Preparation of a vaccine for SCC by transfection of the modified fibroblasts with a 357 bp fragment of the gene for cytochrome P450 (Cyp2e1) A vaccine for KLN205 cells was prepared by transfection of the modified fibroblasts with a 357 bp fragment of the Microarrays of cells from the immuno high pool 6.10.1 were compared with the arrays of cells from the immuno low pool 9.6.2 after three rounds of positive or negative immune selection. The quality of the RNA sample was assessed using an Agilent Bioanalyzer with the RNA6000 Nano Lab Chip (Agilent Technologies). CodeLink Mouse Whole-Genome arrays were comprised of approximately 36 000 30-mer probes designed to conserved exons across the transcripts of targeted genes. Oligo chips of 19,916 genes were analyzed and the upregulated genes more than twofold in immuno high /immuno low pools are listed in this table. 
Discussion
Under appropriate circumstances, cell-based tumor vaccines can activate antitumor immune responses that result in the destruction of cancer cells that express TAA. Successful immunotherapy can become an important part of the overall management of cancer patient. Among other advantages, the immunity is tumor specific, and there is little or no toxicity. Various clinical trials are in progress that are designed to test immune-based therapies for patients with various types of malignancies including SCCHN.
However, not all vaccines are equally successful in inducing therapeutic immune responses. 35 Secondary considerations such as immune tolerance to the antigen chosen for therapy or the generation of regulatory T cells that inhibit tumor immunity are important variables. Tumors such as SCCHN can be highly immunosuppressive. [36] [37] [38] [39] In this report, we describe a new strategy to identify antigens associated with SCC that induce therapeutic immune responses. The effects of the vaccine were tested in mice bearing tumors derived from KLN205 cells, a highly malignant squamous carcinoma cell line. The vaccine was prepared by transfer of genomic DNA fragments from the SCC into a mouse fibroblast cell line that expressed defined (allogeneic) MHC class I determinants. Preparation of the vaccine by transfer of DNA Identification of a squamous carcinoma antigen I O-Sullivan et al from the SCC into a highly immunogenic cell line was an extension of classic findings indicating that transferred DNA integrates spontaneously into the genome of the recipient cells and is expressed. 40, 41 Oncogenes were first discovered by this approach. 42, 43 The protocol used to prepare the vaccine was designed to identify TAA characteristic of the SCC, which induced therapeutic antitumor immune responses in tumor-bearing mice. Cellular vaccines were established and enriched for TAA-positive cells. The enrichment strategy depended upon the identification of cell pools that induced immune responses directed toward the SCC to the greatest extent in syngeneic mice, as determined by two independent assays. After three rounds of enrichment, microarrays of cells from the immuno high and immuno low pools were compared. One of six candidate genes analyzed, the gene for cytochrome P450, was expressed in cells in the immuno high but not the immuno low pool. The immunotherapeutic properties of the fibroblasts, modified to express a 357 bp fragment of the gene (LM-IL-2K b / Cyp2e1 cells), were tested in mice with established tumors derived from KLN205 cells. The therapeutic properties of the vaccine were indicated by the responses of tumorbearing mice treated by immunization with the vaccine. The treated mice survived significantly longer than mice in various control groups. At times, the mice appeared to have rejected the SCC. They survived indefinitely.
Cyp2e1 is a variant of cytochrome P450 2e1. A 357 bp fragment of the gene was identified as specifying a therapeutic TAA by this approach. Cytochrome P450 is a widely distributed enzyme that catalyzes metabolic inactivation of various toxic agents such as N-nitrosodimethylamine, benzene and N-nitrosonornicotine found in cigarette smoke. Tobacco use is a well known major risk factor for SCCHN. 44, 45 Various alleles of cytochrome P450 including Cyp2e1 have been identified by other means as antigens associated with SCCHN cells and other types of neoplastic diseases. [45] [46] [47] [48] [49] It is likely that the enrichment strategy to resulted in an increase in the number of cells in the immuno high pools that expressed the epitope specified by the 357 bp fragment of the gene for Cyp2e1. The immunogenic properties of non-transfected fibroblasts, or cells from the immuno low pool of transfected cells were clearly less than those of cells from the immuno high pool. Microarrays have been used to compare gene expression profiles of malignant and non-malignant cells for various purposes including the identification of TAA. In this study, comparisons of immunotherapeutic and non-therapeutic cells identified Cyp2e1 as including an epitope uniquely expressed in cell vaccines enriched for cells that promoted tumor immunity. This strategy, which combined the identification of immunogenic TAA with the therapeutic response in tumor-bearing animals, raises the possibility that an analogous approach could be used to generate a vaccine of enhanced effectiveness for use in the treatment of patients with SCCHN, and possibly other histologic types of cancer as well. 
